Cullinan Therapeutics, Inc.
CGEM
Positions held
Your positionsCGEM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Cullinan Therapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and high returns for investors as new treatments are developed and approved.
- Cullinan Therapeutics has a market capitalization of approximately $998.7 million, indicating a substantial presence in the market.
- The average target price for CGEM is $33.45, suggesting significant upside potential from its current trading levels.
- The company has reported no revenue for several consecutive quarters, which raises concerns about its operational viability and ability to generate income.
- Cullinan Therapeutics has a net income of -53.704 million for Q2 2026, continuing a trend of negative earnings over the past several quarters.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment and technical indicators suggesting further declines.
Fundamentals
| Market cap | $950.14M | Enterprise value | $662.46M | Trailing P/E | — | Forward P/E | -6.14 |
| PEG | — | Price / book | 3.09 | Beta | -0.04 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -50.3% | ROA | -31.4% | Debt / equity | 0.01 |
| Current ratio | 8.42 | Free cash flow | -$89.23M | Analyst recommendation | strong_buy | Mean target | $33.45 |
| 52w high | $23.19 | 52w low | $6.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$53.7M | -$49.7M | -$50.7M | -$50.6M | -$70.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$57.3M | -$53.7M | -$55.3M | -$55.6M | -$75.8M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$220M | -$167M | -$153M | $111M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$242M | -$197M | -$191M | -$132M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Cullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid Leukemia
2026-10-02 · Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
2026-10-02 · Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer
2026-09-28 · Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
2026-09-26 · Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
2026-09-24 · CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
2026-09-24 · Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
2026-09-24 · Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data
Price (daily)
Full chart · RSI · MACD · patterns